Division of Urology, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA.
J Urol. 2010 Jul;184(1):69-73. doi: 10.1016/j.juro.2010.03.030. Epub 2010 May 15.
We evaluated the value of hydronephrosis, ureteroscopic biopsy grade and urinary cytology to predict advanced upper tract urothelial carcinoma.
We reviewed the charts of 469 patients with upper tract urothelial carcinoma treated with radical nephroureterectomy or distal ureterectomy. Complete data on hydronephrosis (present vs absent), ureteroscopic grade (high vs low) and urinary cytology (positive vs negative) were available in 172 patients. The outcome was muscle invasive (pT2-pT4) or nonorgan confined (pT3 or greater, or lymph node metastasis) upper tract urothelial carcinoma.
Of the patients 92 (54%) had hydronephrosis, 74 (43%) had high grade disease on ureteroscopic biopsy and 137 (80%) had positive cytology. On univariate analysis hydronephrosis (p <0.001), high ureteroscopic grade (p <0.001) and positive cytology (p = 0.03) were associated with muscle invasive and nonorgan confined disease. On multivariate analysis adjusting for tumor site, gender and age hydronephrosis and high ureteroscopic grade were associated with muscle invasive carcinoma (HR 12.0 and 4.5, respectively, each p <0.001) but cytology was not (HR 2.3, p = 0.17). However, all 3 variables were independently associated with nonorgan confined disease (HR 5.1, p <0.001; HR 3.9, p <0.001; and HR 3.1, p = 0.035, respectively). Combining these 3 tests incrementally improved the prediction of upper tract urothelial carcinoma stage. Abnormality of all 3 tests had 89% and 73% positive predictive value for muscle invasive and nonorgan confined upper tract urothelial carcinoma, respectively, but when all tests were normal, the negative predictive value was 100%.
Preoperative evaluation for hydronephrosis, ureteroscopic grade and cytology can identify patients at risk for advanced upper tract urothelial carcinoma. Such knowledge may impact surgery choice and extent as well as the need for perioperative chemotherapy regimens.
我们评估了肾积水、输尿管镜活检分级和尿液细胞学在预测上尿路上皮癌进展中的价值。
我们回顾了 469 例接受根治性肾输尿管切除术或远端输尿管切除术治疗的上尿路上皮癌患者的病历。在 172 例患者中,有完整的肾积水(存在/不存在)、输尿管镜分级(高/低)和尿液细胞学(阳性/阴性)数据。结局为肌层浸润性(pT2-pT4)或非器官局限性(pT3 或更高,或淋巴结转移)上尿路上皮癌。
在患者中,92 例(54%)有肾积水,74 例(43%)输尿管镜活检分级较高,137 例(80%)尿液细胞学阳性。单因素分析显示,肾积水(p<0.001)、输尿管镜活检分级较高(p<0.001)和细胞学阳性(p=0.03)与肌层浸润性和非器官局限性疾病相关。多因素分析调整肿瘤部位、性别和年龄后,肾积水和输尿管镜活检分级较高与肌层浸润性癌相关(HR 分别为 12.0 和 4.5,均 p<0.001),但细胞学检查结果并非如此(HR 2.3,p=0.17)。然而,所有 3 个变量均与非器官局限性疾病独立相关(HR 分别为 5.1、p<0.001;HR 3.9、p<0.001;HR 3.1、p=0.035)。这 3 个检测联合应用可逐步提高对上尿路上皮癌分期的预测能力。所有 3 项检测均异常时,肌层浸润性和非器官局限性上尿路上皮癌的阳性预测值分别为 89%和 73%,但当所有检测均正常时,阴性预测值为 100%。
术前评估肾积水、输尿管镜分级和细胞学检查可识别上尿路上皮癌进展风险较高的患者。此类知识可能影响手术选择和范围以及围手术期化疗方案的需要。